BOCX Exposed less than 40 m shares outstanding

[jokesola]

This might be nest IMGG. BOCX cheap with lots of interests in the last couple of days.
Our New Bio Pick is BOCX!!!!! - Google Docs

[waves]

There are limited information regarding this company from Yahoo, Google, and the co. website. From the available press release, we only know it has totally about 44 mm shares, and they raised recently about $394K. Do you know if and when they will fill 510K for market clearance for their device? Their device looks promising.

[jokesola]

This is what i have gathered. Another press release is coming on Monday. I will update you. I think it's very cheap r

BioCurex, Inc. (“BioCurex” or “the Company”) is a biotechnology company developing products for cancerdiagnosis, imaging, and therapy that target a global oncology market forecast to reach over $50 billion by
2009. The Company uses a novel, patented technology based on the RECAF™ cancer marker, discovered
by Dr. Ricardo Moro-Vidal, BioCurex’s chief executive officer (CEO), president, and founder. RECAF™ is a
molecule found on malignant† cells but absent from most normal or benign cells. BioCurex believes that the
detection of this molecule in tissue or serum samples is the foundation for new cancer diagnostic tests and
imaging techniques. The RECAF™ marker has been found on every cancer tissue that BioCurex has studied
to date, including on many common, severe cancers: breast, lung, gastric, prostate, and leukemia. This
characteristic indicates that RECAF™ is capable of detecting more than one type of cancer, which is a
limitation of many currently available cancer markers. The Company’s RECAF™ technology is reported to
have high levels of clinical sensitivity and specificity (measures of cancer marker accuracy), successfully
detecting over 90% of cancer in blood and tissue samples. A serum-based assay using RECAF™ recently
identified twice as many prostate cancers as the current standard for prostate cancer detection, the prostatespecific antigen (PSA) test. A RECAF™-based test also detected 90% to 93% of Stage I and Stage II (early stage) breast cancer samples, without any false positives. This data supports BioCurex’s aim of reducing
human suffering through the early detection of cancer or cancer recurrence after treatment. Moreover, due to
its ability to differentiate between cancerous and normal cells, RECAF™ technology may facilitate the
administration of targeted therapeutics that attack cancer cells but do not damage healthy tissue.

Key Points

BioCurex maintains semi-exclusive license agreements with Abbott Laboratories (ABT-NYSE) and
Inverness Medical Innovations, Inc. (IMA-AMEX) to commercialize products using RECAF™
technology. These licenses benefit BioCurex through the payment of milestone fees and royalties, as
well as by giving the Company access to independent diagnostic expertise and validation of RECAF™.


The Company has developed two diagnostic kits that identify cancerous tissue versus normal or benigntissue by targeting RECAF™: (1) Histo-RECAF™ (approved in the U.S. as a Class I Medical Device);
and (2) Cryo-RECAF™. The Company is also finalizing Serum-RECAF™, an assay to detect RECAF™
levels in a patient’s blood. Other product areas include tumor imaging and the development of a Rapid
Test for initial point-of-care cancer detection.


As of 2005, global laboratory diagnostic tests exceeded $25 billion each year, with molecular diagnostictesting growing by roughly 20% annually and estimated to be over $5 billion by 2009. In the diagnostics
market, cancer testing, which is dominated by serum-based cancer markers, recently exceeded $2
billion and is expected to experience some of the greatest growth over the next three to five years.


BioCurex’s management team has brought a research technology toward commercialization in arelatively short timeframe while also negotiating beneficial license agreements. The Company’s
Scientific Advisory Board (SAB) includes leaders in the global cancer marker field.


Patents in over 20 countries. Granted patents in the USA, the European Union, Russia and China

more information on bocx
BioCurex, Inc. (BOCX) - Company Profile